Bevacizumab and neurodevelopmental outcomes of preterm infants with retinopathy of prematurity: should we still worry?
Pelin CelikIclal Ayranci SucakliCaner Karaİkbal Seza PetriçliSumru KavurtIstemi Han CelikAhmet Yağmur BaşNihal DemirelPublished in: The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians (2021)
Patients treated with bevacizumab should be carefully monitored for neurodevelopmental problems, although the frequency of grades 3 and 4 IVH in the bevacizumab group is thought to contribute to higher rates of sNDI and Bayley-III score <70.